Jun 2026 (Q2 FY26) — Aug 4, 2026
Bruker Q2 FY26 — Return to Organic Growth and Strong Deep Tech Orders
Read the full callBruker (BRKR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Bruker earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 839 | +5.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -7.8 | −9.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -52.0 | −784.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
11 of 21 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Organic revenue growth | low to mid-single digits percentage | Mar 2026 | Our Q2 '26 reported revenues of $839 million increased 5.2% year-over-year with organic growth of 2.8% or 3.4% organic growth, excluding tariff refunds in the second quarter. | Achieved |
| Additional cost reductions | $20 million | Jun 2026 | This new structure is expected to drive an additional $20 million of cost reductions in fiscal year '27. | New |
10 of BRUKER CORP's 46 targets were missed. See which ones, and which are quietly gone. The 2 above are the free sample; 44 more targets are in the full ledger.
Claimed
- Returned to organic revenue growth of 2.8% in Q2 FY26, or 3.4% excluding tariff refunds.
- Scientific Instruments segment achieved 10% organic bookings growth year-over-year, with book-to-bill above 1.0 for the fourth consecutive quarter.
- Deep tech semiconductor tools and energy research technologies saw over 50% organic order growth year-over-year in Q2.
- Non-GAAP diluted EPS increased 53% to $0.49 in Q2 FY26, driven by cost reductions and tariff refunds.
- Achieved $30 million in cost savings in Q2, on track for $140 million annualized savings in FY26.
Qualified
- U.S. academic orders remained weak in Q2, with U.S. ACA/GOV revenues down more than $15 million year-over-year.
- Asia Pacific revenue declined in the low double digits percentage in Q2, including a low double-digit decline in China.
- Q2 FY26 reported revenues were at the low end of expectations, unfavorably impacted by tariff refunds (on revenue growth) and a stronger U.S. dollar.
- Non-GAAP effective tax rate increased to 25% from 23.6% in Q2 FY25.
- GAAP results include a noncash goodwill impairment charge of $135 million related to automation and spatial biology businesses.
Price
$55.37 +1.04% · +$0.57
Performance +49.7% 1Y
1Y: $36.98 on 17 Oct 2025 → $55.37. High $64.75 (30 Sept 2026), low $32.76 (16 Mar 2026).
- Previous close
- $54.8
- 52-week range
- $32.76 – $64.75
- One year
- +45.29%
Overview
- Symbol
- BRKR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
11 of 21 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Organic revenue growth | low to mid-single digits percentage | Mar 2026 | Our Q2 '26 reported revenues of $839 million increased 5.2% year-over-year with organic growth of 2.8% or 3.4% organic growth, excluding tariff refunds in the second quarter. | Achieved |
| Additional cost reductions | $20 million | Jun 2026 | This new structure is expected to drive an additional $20 million of cost reductions in fiscal year '27. | New |
Claimed
- Returned to organic revenue growth of 2.8% in Q2 FY26, or 3.4% excluding tariff refunds.
- Scientific Instruments segment achieved 10% organic bookings growth year-over-year, with book-to-bill above 1.0 for the fourth consecutive quarter.
- Deep tech semiconductor tools and energy research technologies saw over 50% organic order growth year-over-year in Q2.
- Non-GAAP diluted EPS increased 53% to $0.49 in Q2 FY26, driven by cost reductions and tariff refunds.
- Achieved $30 million in cost savings in Q2, on track for $140 million annualized savings in FY26.
Qualified
- U.S. academic orders remained weak in Q2, with U.S. ACA/GOV revenues down more than $15 million year-over-year.
- Asia Pacific revenue declined in the low double digits percentage in Q2, including a low double-digit decline in China.
- Q2 FY26 reported revenues were at the low end of expectations, unfavorably impacted by tariff refunds (on revenue growth) and a stronger U.S. dollar.
- Non-GAAP effective tax rate increased to 25% from 23.6% in Q2 FY25.
- GAAP results include a noncash goodwill impairment charge of $135 million related to automation and spatial biology businesses.
The full ledger
Open BRUKER CORP’s full ledger
A free account opens 5 company ledgers a month. All 46 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 6, 2026
Bruker Corporation Q1 FY26 — Strong Bookings and Cost Savings Drive Q1 Beat
Read the full callEvery analysed call
Bruker earnings calls (BRKR)
Financials
What the filings say
Net profit, year on year: −784% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 864 | 980 | 801 | 797 | 861 | 977 | 823 | 839 |
| Operating profit | 68 | 72 | 32 | 12 | -52 | 76 | 10 | -65 |
| Operating margin | 7.9% | 7.4% | 4.0% | 1.5% | −6.0% | 7.8% | 1.2% | −7.8% |
| Other income | -13 | -16 | -7 | -11 | -20 | -8 | 12 | 25 |
| Interest | 12 | 16 | 13 | 16 | 20 | 11 | 12 | 18 |
| Profit before tax | 55 | 56 | 25 | 1 | -72 | 68 | 22 | -41 |
| Tax rate | 26.8% | 72.5% | 34.7% | −620.0% | 19.6% | 55.4% | 11.4% | −34.9% |
| Net profit | 41 | 14 | 17 | 8 | -60 | 26 | 14 | -52 |
| EPS ($ per share) | 0.27 | — | 0.11 | 0.05 | -0.41 | — | 0.02 | -0.41 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | — | — | — | — | — | 2 | 2 |
| Reserves | 1,103 | 1,275 | 1,407 | 1,660 | 1,926 | 2,324 | 2,407 | 2,362 |
| Total liabilities | 1,224 | 1,854 | 2,075 | 2,565 | 2,480 | 2,837 | 3,992 | 3,731 |
| Fixed assets | 271 | 306 | 396 | 406 | 487 | 600 | 669 | 745 |
| Investments | 0 | 7 | 50 | 100 | 0 | — | — | — |
| Total assets | 2,129 | 2,772 | 3,049 | 3,650 | 3,612 | 4,250 | 5,807 | 6,241 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 240 | 213 | 332 | 282 | 274 | 350 | 251 | 134 |
| Cash from investing | -123 | -158 | -193 | -192 | -252 | -326 | -1,757 | -196 |
| Cash from financing | -112 | 300 | -162 | 319 | -415 | -193 | 1,230 | 135 |
| Net cash flow | -3 | 356 | 4 | 386 | -423 | -157 | -305 | 116 |
| Capital expenditure | -49 | -73 | -97 | -92 | -129 | -107 | -115 | -91 |
| Free cash flow | 191 | 140 | 235 | 190 | 145 | 243 | 136 | 43 |
BRKR revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Bsi Calid | — | — | 35% | 36% | 36% | 34% | 38% | 37% | +8.6% |
| Bsi Nano | — | — | 32% | 32% | 31% | 32% | 30% | 31% | +3.6% |
| Bsi Biospin | — | — | 26% | 24% | 24% | 27% | 24% | 23% | +0.2% |
| Energy and Supercon Technologies | 8% | 6% | 7% | 8% | 8% | 7% | 8% | 8% | +10.9% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 30% ↑ 2 pt
- Europe Excluding Germany 29%
- Asia Pacific Excluding China 13%
- CN 13% ↓ 2 pt
- DE 8% ↓ 1 pt
- Other Country 8% ↓ 1 pt
As BRKR cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
62 filings between Nov 6, 2025 and Sep 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$3.61M
16 sales by 4 insiders
Compensation
not trading decisions- 18
- Award — granted as compensation
- 15
- Option exercise — converted options into shares
- 13
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Munch Mark | — | $2.93M | Sep 15, 2026 |
| PACKER RICHARD A | — | $243.2K | Dec 1, 2025 |
| ORNELL JOHN A | — | $243.1K | Nov 6, 2025 |
| Pusch Wolfgang | — | $197.6K | Aug 17, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Sale | 2,000 | $105.7K |
| Sep 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Option exercise | 2,000 | $44.4K |
| Aug 17, 2026 | Pusch Wolfgang President BMID Group | Sale | 3,473 | $197.6K |
| Aug 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Tax withheld | 2,984 | $172.2K |
| Aug 15, 2026 | Pusch Wolfgang President BMID Group | Award | 3,120 | $0 |
| Aug 15, 2026 | LAUKIEN FRANK H PRESIDENT & CEO | Award | 29,463 | $0 |
| Aug 15, 2026 | LAUKIEN FRANK H PRESIDENT & CEO | Tax withheld | 4,760 | $274.7K |
| Aug 15, 2026 | Herman Gerald N EXECUTIVE VICE PRESIDENT, CFO | Tax withheld | 2,724 | $157.2K |
| Aug 15, 2026 | Prause Burkhard PRES. & CEO, BRUKER BEST | Award | 3,303 | $0 |
| Aug 15, 2026 | Srega Juergen PRESIDENT CALID | Award | 16,898 | $0 |
| Aug 15, 2026 | Bures Thomas Chief Accounting Officer | Award | 4,035 | $0 |
| Aug 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Award | 14,443 | $0 |
| Aug 15, 2026 | Herman Gerald N EXECUTIVE VICE PRESIDENT, CFO | Award | 15,794 | $0 |
| Aug 14, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Sale | 2,000 | $115.2K |
| Aug 14, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Option exercise | 2,000 | $44.4K |
| Aug 11, 2026 | Herman Gerald N EXECUTIVE VICE PRESIDENT, CFO | Tax withheld | 1,410 | $80.4K |
| Aug 11, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Tax withheld | 1,619 | $92.3K |
| Aug 11, 2026 | LAUKIEN FRANK H PRESIDENT & CEO | Tax withheld | 4,838 | $275.9K |
| Aug 10, 2026 | Herman Gerald N EXECUTIVE VICE PRESIDENT, CFO | Tax withheld | 1,289 | $72.6K |
| Aug 10, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Tax withheld | 1,573 | $88.6K |
| Aug 10, 2026 | LAUKIEN FRANK H PRESIDENT & CEO | Tax withheld | 4,564 | $257.0K |
| Aug 9, 2026 | LAUKIEN FRANK H PRESIDENT & CEO | Tax withheld | 2,361 | $126.1K |
| Aug 9, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Tax withheld | 1,904 | $101.7K |
| Aug 9, 2026 | Herman Gerald N EXECUTIVE VICE PRESIDENT, CFO | Tax withheld | 1,600 | $85.5K |
| Jul 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Sale | 2,000 | $120.5K |
| Jul 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Option exercise | 2,000 | $44.4K |
| Jun 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Option exercise | 2,000 | $44.4K |
| Jun 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Sale | 2,000 | $109.5K |
| May 15, 2026 | Bernard Thierry Director | Award | 2,886 | $0 |
| May 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Sale | 2,000 | $87.8K |
| May 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Option exercise | 2,000 | $44.4K |
| Apr 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Sale | 2,000 | $79.8K |
| Apr 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Option exercise | 2,000 | $44.4K |
| Mar 13, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Option exercise | 2,000 | $44.4K |
| Mar 13, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Sale | 2,000 | $70.9K |
| Feb 15, 2026 | Friend Cynthia M Director | Award | 4,520 | $0 |
| Feb 15, 2026 | Phillips Jack Director | Award | 4,520 | $0 |
| Feb 15, 2026 | FRANCIS LAURA Director | Award | 4,520 | $0 |
| Feb 15, 2026 | Requardt Hermann Fritz Director | Award | 4,520 | $0 |
| Feb 15, 2026 | Anderson Bonnie H Director | Award | 4,520 | $0 |
| Feb 15, 2026 | ORNELL JOHN A Director | Award | 4,520 | $0 |
| Feb 15, 2026 | Perkins Adelene Q Director | Award | 4,520 | $0 |
| Feb 15, 2026 | LINTON WILLIAM A Director | Award | 4,520 | $0 |
| Feb 15, 2026 | PACKER RICHARD A Director | Award | 4,520 | $0 |
| Feb 15, 2026 | ROSENTHAL BOB Director | Award | 4,520 | $0 |
| Feb 15, 2026 | Bures Thomas Chief Accounting Officer | Tax withheld | 274 | $10.0K |
| Feb 13, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Sale | 2,000 | $73.9K |
| Feb 13, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Option exercise | 2,000 | $44.4K |
| Jan 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Sale | 2,000 | $98.4K |
| Jan 15, 2026 | Munch Mark EXEC VP&PRES BRUKER NANO INC. | Option exercise | 2,000 | $44.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for BRUKER CORP
Free account. Everything above stays public.
Write why you follow BRUKER CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading